Table 1

Screening analysis of exogenous compounds glucuronidated by the UGT2B17 enzyme

 4-Methylumbelliferone+ Borneol+
 Umbelliferone+ Menthol+
 Scopoletin+ Harmol
 4-OH-coumarin Codeine
NSAID Morphine
 Acetyl salicylic acid Naltrexone
 Indomethacin Chloramphenicol
 Salicylic acid 17β-Ethynylestradiol
Anthraquinones Hydroxyflutamide
 Anthraflavic acid+ Furosemide
 Quinizarin 6-Hydroxyquinoline
 Emodin+ 8-Hydroxyquinoline
 Alizarin+ Hecogenin
BenzodiazepinsPhenolic compounds
 Chlordiazepoxide (Librium) 4-Ethyl phenol+
 Diazepam (Valium) 4-Propyl phenol+
 Lorazepam (Ativan) 4-T-buthyl phenol
 Oxazepam (Serax) Eugenol+
Flavonoids 1-Naphthol+
 Naringenin Phenol red+
 Chrysin+ Acetaminophen
 Galangin+ Caffeic acid
 Apigenin Ferrulic acid
 Baicalein Pyrogallol
 Fisetin Carvacrol
 Quercetin Thymol
 Biochenin A α-Naphtylamine

To screen for substrates that react with the UGT2B17 enzyme, 200 μM of each compound was incubated in the presence of 15 μM [14C]UDPGA, 100 μM unlabeled UDPGA for 16 h at 37oC, and 11 μg of microsomal proteins from HK293 cells stably expressing UGT2B17 enzyme. +, glucuronidation activity was observed; −, no conjugation was observed.